176 related articles for article (PubMed ID: 12109343)
1. Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database.
Stephenson RA
Urol Clin North Am; 2002 Feb; 29(1):173-81. PubMed ID: 12109343
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.
Welch HG; Albertsen PC
J Natl Cancer Inst; 2009 Oct; 101(19):1325-9. PubMed ID: 19720969
[TBL] [Abstract][Full Text] [Related]
3. Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-A population-based analysis of 2 national cohorts.
Helgstrand JT; Røder MA; Klemann N; Toft BG; Lichtensztajn DY; Brooks JD; Brasso K; Vainer B; Iversen P
Cancer; 2018 Jul; 124(14):2931-2938. PubMed ID: 29723398
[TBL] [Abstract][Full Text] [Related]
4. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study.
Collin SM; Martin RM; Metcalfe C; Gunnell D; Albertsen PC; Neal D; Hamdy F; Stephens P; Lane JA; Moore R; Donovan J
Lancet Oncol; 2008 May; 9(5):445-52. PubMed ID: 18424233
[TBL] [Abstract][Full Text] [Related]
5. The role of increasing detection in the rising incidence of prostate cancer.
Potosky AL; Miller BA; Albertsen PC; Kramer BS
JAMA; 1995 Feb; 273(7):548-52. PubMed ID: 7530782
[TBL] [Abstract][Full Text] [Related]
6. Impact of screening on incidence and mortality of prostate cancer in the United States.
Potosky AL; Feuer EJ; Levin DL
Epidemiol Rev; 2001; 23(1):181-6. PubMed ID: 11588846
[TBL] [Abstract][Full Text] [Related]
7. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.
Etzioni R; Penson DF; Legler JM; di Tommaso D; Boer R; Gann PH; Feuer EJ
J Natl Cancer Inst; 2002 Jul; 94(13):981-90. PubMed ID: 12096083
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of localized prostate cancer following conservative management.
Lu-Yao GL; Albertsen PC; Moore DF; Shih W; Lin Y; DiPaola RS; Barry MJ; Zietman A; O'Leary M; Walker-Corkery E; Yao SL
JAMA; 2009 Sep; 302(11):1202-9. PubMed ID: 19755699
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen testing for prostate cancer: Depleting a limited pool of susceptible individuals?
Valberg M; Grotmol T; Tretli S; Veierød MB; Moger TA; Devesa SS; Aalen OO
Eur J Epidemiol; 2017 Jun; 32(6):511-520. PubMed ID: 27431530
[TBL] [Abstract][Full Text] [Related]
10. National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening.
Farkas A; Schneider D; Perrotti M; Cummings KB; Ward WS
Urology; 1998 Sep; 52(3):444-8; discussion 448-9. PubMed ID: 9730458
[TBL] [Abstract][Full Text] [Related]
11. Impact of screening on prostate cancer rates and trends.
Mettlin C
Microsc Res Tech; 2000 Dec; 51(5):415-8. PubMed ID: 11074610
[TBL] [Abstract][Full Text] [Related]
12. Comparison of prostate cancer survival in Germany and the USA: can differences be attributed to differences in stage distributions?
Winter A; Sirri E; Jansen L; Wawroschek F; Kieschke J; Castro FA; Krilaviciute A; Holleczek B; Emrich K; Waldmann A; Brenner H;
BJU Int; 2017 Apr; 119(4):550-559. PubMed ID: 27208546
[TBL] [Abstract][Full Text] [Related]
13. Cost implications and complications of overtreatment of low-risk prostate cancer in the United States.
Aizer AA; Gu X; Chen MH; Choueiri TK; Martin NE; Efstathiou JA; Hyatt AS; Graham PL; Trinh QD; Hu JC; Nguyen PL
J Natl Compr Canc Netw; 2015 Jan; 13(1):61-8. PubMed ID: 25583770
[TBL] [Abstract][Full Text] [Related]
14. Temporal trends in cause of death among Swedish and US men with prostate cancer.
Epstein MM; Edgren G; Rider JR; Mucci LA; Adami HO
J Natl Cancer Inst; 2012 Sep; 104(17):1335-42. PubMed ID: 22835388
[TBL] [Abstract][Full Text] [Related]
15. Population-based prostate cancer trends in the United States: patterns of change in the era of prostate-specific antigen.
Stephenson RA; Stanford JL
World J Urol; 1997; 15(6):331-5. PubMed ID: 9436281
[TBL] [Abstract][Full Text] [Related]
16. Trade-Off between Treatment of Early Prostate Cancer and Incidence of Advanced Prostate Cancer in the Prostate Screening Era.
Shen X; Kumar P
J Urol; 2016 May; 195(5):1397-1402. PubMed ID: 26656266
[TBL] [Abstract][Full Text] [Related]
17. Prostate carcinoma incidence and patient mortality: the effects of screening and early detection.
Brawley OW
Cancer; 1997 Nov; 80(9):1857-63. PubMed ID: 9351560
[TBL] [Abstract][Full Text] [Related]
18. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.
; Grossman DC; Curry SJ; Owens DK; Bibbins-Domingo K; Caughey AB; Davidson KW; Doubeni CA; Ebell M; Epling JW; Kemper AR; Krist AH; Kubik M; Landefeld CS; Mangione CM; Silverstein M; Simon MA; Siu AL; Tseng CW
JAMA; 2018 May; 319(18):1901-1913. PubMed ID: 29801017
[TBL] [Abstract][Full Text] [Related]
19. Clarifying uncertainty regarding detection and treatment of early-stage prostate cancer.
Wilt TJ
Semin Urol Oncol; 2002 Feb; 20(1):10-7. PubMed ID: 11828353
[TBL] [Abstract][Full Text] [Related]
20. Prevention of Prostate Cancer Morbidity and Mortality: Primary Prevention and Early Detection.
Barry MJ; Simmons LH
Med Clin North Am; 2017 Jul; 101(4):787-806. PubMed ID: 28577627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
